A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 44,100 shares of MIRM stock, worth $1.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,100
Previous 24,700 78.54%
Holding current value
$1.93 Million
Previous $844,000 103.67%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$33.68 - $44.74 $6.54 Million - $8.69 Million
-194,215 Reduced 12.25%
1,391,409 $54.3 Million
Q2 2024

Aug 14, 2024

BUY
$23.57 - $34.85 $4.55 Million - $6.73 Million
193,118 Added 13.87%
1,585,624 $54.2 Million
Q1 2024

May 15, 2024

SELL
$24.92 - $30.02 $1.25 Million - $1.51 Million
-50,306 Reduced 3.49%
1,392,506 $35 Million
Q4 2023

Feb 14, 2024

SELL
$27.14 - $34.93 $7.45 Million - $9.59 Million
-274,445 Reduced 15.98%
1,442,812 $42.6 Million
Q3 2023

Nov 14, 2023

BUY
$24.63 - $32.85 $7.08 Million - $9.44 Million
287,412 Added 20.1%
1,717,257 $54.3 Million
Q2 2023

Aug 14, 2023

BUY
$23.51 - $30.09 $1.42 Million - $1.82 Million
60,500 Added 4.42%
1,429,845 $37 Million
Q1 2023

May 15, 2023

SELL
$19.19 - $24.1 $752,516 - $945,057
-39,214 Reduced 2.78%
1,369,345 $32.9 Million
Q4 2022

Feb 14, 2023

BUY
$17.59 - $23.83 $8.5 Million - $11.5 Million
483,382 Added 52.25%
1,408,559 $27.5 Million
Q3 2022

Nov 14, 2022

BUY
$19.98 - $29.44 $9.9 Million - $14.6 Million
495,330 Added 115.23%
925,177 $19.4 Million
Q2 2022

Aug 15, 2022

BUY
$18.42 - $27.5 $1.78 Million - $2.66 Million
96,819 Added 29.07%
429,847 $8.37 Million
Q1 2022

May 16, 2022

BUY
$15.5 - $23.93 $3.2 Million - $4.94 Million
206,602 Added 163.42%
333,028 $7.33 Million
Q4 2021

Feb 14, 2022

BUY
$13.05 - $19.35 $521,321 - $772,993
39,948 Added 46.19%
126,426 $2.02 Million
Q3 2021

Nov 15, 2021

BUY
$13.95 - $20.18 $1.21 Million - $1.75 Million
86,478 New
86,478 $1.72 Million
Q1 2021

May 17, 2021

SELL
$16.29 - $21.92 $251,468 - $338,379
-15,437 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$15.75 - $25.45 $180,211 - $291,198
-11,442 Reduced 42.57%
15,437 $269,000
Q3 2020

Nov 16, 2020

BUY
$18.4 - $26.59 $252,852 - $365,399
13,742 Added 104.61%
26,879 $518,000
Q2 2020

Aug 14, 2020

BUY
$11.51 - $20.97 $151,206 - $275,482
13,137 New
13,137 $256,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.61B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.